Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Technological Advances in Glucose Management in Older Adults (TANGO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03078491
Recruitment Status : Recruiting
First Posted : March 13, 2017
Last Update Posted : August 17, 2018
Sponsor:
Collaborators:
Beth Israel Deaconess Medical Center
Boston Children’s Hospital
RTI International
Information provided by (Responsible Party):
Joslin Diabetes Center

Brief Summary:
This is a study to assess the effectiveness of CGM (Continuous Glucose Monitor), enhanced by a diabetes management platform (DMP), collectively called enhanced CGM (eCGM), in the care of older patients with T1D. The DMP includes an automated data transfer from CGM, insulin-delivery devices, and activity tracker to a clinical decision support system (CDS) that provides dosing adjustment recommendations based on that data to the healthcare team. In addition, the DMP includes on-demand education for patients and caregivers, and an interface for communication between providers, patients, and their caregivers.

Condition or disease Intervention/treatment Phase
Type 1 Diabetes Mellitus Older Adults Hypoglycemia Other: eCGM (enhanced CGM) Not Applicable

Detailed Description:
Hypoglycemia is a major and often devastating complication of T1D in the elderly. CGM has been shown to reduce the risk for hypoglycemia in adults with T1D including some more functional patients over 65 years old. However, the Medicare population is heterogeneous and may have age-related clinical and functional impairments that can impact self-care. These patients will require additional targeted guidance and support to fully realize the potential benefits of CGM. To address these age-specific barriers which could limit the effective use of CGM, in our planned RCT (Specific Aim 1) the use of CGM will be coupled with the DMP (Diabetes Management Platform), a tablet-based technology platform ( termed enhanced CGM (eCGM)). The CGM, insulin delivery, and activity data uploaded from the DMP will be analyzed by the clinical decision support system (CDS), which will provide insulin dosing recommendations to the study physicians, who will then accept or reject changes in therapy. The use of the DMP is expected to help the less technologically proficient Medicare patients to derive benefit from CGM. Specific Aim 2 will involve extensive mixed methods research (including semi-structured interviews of patients and caregivers) directed at making an in-depth assessment of barriers to the use of diabetes technology in older adults. This investigation will provide the evidence-base for future improvements in both the technology and clinical approach to the training of older adults and their caregivers. Specific Aim 3 will involve a cost-effectiveness analysis of the technology system (CGM with DMP = enhanced CGM [eCGM]) used in the trial as well as quality of life measures, providing a foundation for decision-making on coverage.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 168 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Technological Advances in Glucose Management in Older Adults
Actual Study Start Date : March 30, 2017
Estimated Primary Completion Date : July 31, 2021
Estimated Study Completion Date : January 1, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hypoglycemia

Arm Intervention/treatment
Experimental: Intervention
The intervention group will use eCGM (CGM with Diabetes Management Platform(DMP)) and an activity meter. The DMP will be pre-loaded with geriatric-specific education material, weblink to online education and surveys. The CGM, insulin delivery, and activity data uploaded from the DMP will be analyzed by the clinical decision support system (CDS), which will provide insulin dosing recommendations to the study physicians, who will then accept or reject changes in therapy. The DMP can also be configured to route the insulin regimen change approved by the study physician to the designated care providers of the patient. Blue-tooth unabled insulin pens will also provide additional data to verify if the patient is taking recommended insulin doses.
Other: eCGM (enhanced CGM)
Glucose (CGM and Bluetooth BG meter), insulin (pump or Bluetooth insulin pen) and activity data will be automatically uploaded via the subjects' tablet computers, and analyzed by the CDS. The CDS will, if indicated generate adjustable insulin dosing recommendations that will compensate for different insulin requirements following high vs low activity days. The recommendations of the CDS will be used by the clinical team in their therapeutic decision-making about insulin dosing adjustments at the scheduled study follow up visits and the remote visits between these in-person visits. In addition, study staff will provide recommendations regarding hypoglycemic warning symptoms, causes, and appropriateness of treatment.

No Intervention: Attention Control
The attention control group will receive an android tablet pre-loaded with activity monitor devices, education material, and weblink to online education and surveys. However, the data will not be analyzed by CDS. An independent physician and a study staff member- only caring for the control group subjects will review the insulin and glucose data at in-person and remote study visits and make appropriate dosing adjustments based on self monitoring glucose levels



Primary Outcome Measures :
  1. Change in duration of hypoglycemia [ Time Frame: change of duration of hypoglycemia(minutes/day) from baseline to 6 months between intervention and control groups ]
    Minutes per day CGM < 70 mg/dL assessed over 2 weeks CGM use (blinded in the control arm; unblinded in the treatment arm)


Secondary Outcome Measures :
  1. Fasting and bedtime CGM glucose values per day [ Time Frame: change in glucose values(mg/dl) from baseline to 6 months between intervention and control groups ]
    Difference from fasting and bedtime CGM glucose values per day

  2. Severe biochemical hypoglycemia [ Time Frame: change in severe biochemical hypoglycemia (episodes per day) from baseline to 6 months between intervention and control groups ]
    Incidence of severe biochemical hypoglycemia (defined as CGM below 54mg/dL for > than 20 minutes) assessed over 2 weeks CGM use (blinded in the control arm; unblinded in the treatment arm)

  3. Severe clinical hypoglycemia [ Time Frame: change in severe clinical hypoglycemia (episodes per day) from baseline to 6 months between intervention and control groups ]
    Incidence of clinically severe hypoglycemia (requiring third party assistance or loss of consciousness) measured by clinical history,

  4. Hemoglobin A1C [ Time Frame: Change in A1C (%) from baseline to 6 months between intervention and control groups ]
    A1C measured by laboratory test

  5. Cost-effectiveness and cost-utility [ Time Frame: 6 months ]
    cost-effectiveness and cost-utility of using eCGM versus usual care with self-monitoring glucose monitoring by calculating the incremental cost-effectiveness ratios

  6. Barriers and facilitators of CGM use [ Time Frame: 6 months ]
    Mixed-method approach using semi-structured interviews to assess barriers and facilitators in those participants who fail the pretrial run-in and those who derive benefits from eCGM



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with age ≥ 65 years
  • Community-living
  • Clinical diagnosis of T1D
  • On multiple insulin injections (≥3 injection/s day) or insulin pump.

Exclusion Criteria:

  • Use of real-time CGM in past 2 years
  • A1c > 10% (since individuals with very poor glycemic control usually have barriers to optimal self-care that preclude effective use of technology)
  • Use of insulin pump that cannot be uploaded for CDS
  • Unable or unwilling to perform task needed for study participation during the run-in period
  • Severe vision or hearing impairment that could interfere with study tasks
  • Need to use acetaminophen on regular basis (since can interfere with CGM accuracy)
  • Living in an institutional setting (e.g. group homes, nursing homes)
  • Terminal diseases with life expectancy < 1 year (e.g. malignancy)
  • Severe comorbidities that prevent completing outcome measurements (e.g. severe dementia, severe vision impairment, severe functional disabilities, inability to perform basic activities of daily living)
  • Alcohol or other drug abuse
  • Conditions that impact wear of CGM (e.g. CHF with edema, skin conditions); and
  • End stage renal insufficiency (eGFR<30), or on dialysis (since impact of fluid shift on sensor lag not clearly understood).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03078491


Contacts
Layout table for location contacts
Contact: Christine Slyne 617-309-4683 christine.slyne@joslin.harvard.edu

Locations
Layout table for location information
United States, Massachusetts
Joslin Diabetes Center Recruiting
Boston, Massachusetts, United States, 02215
Contact: Medha N Munshi, MD    617-632-8676    medha.munshi@joslin.harvard.edu   
Contact: Christine Slyne, BS    617-309-4683    Christine.slyne@joslin.harvard.edu   
Principal Investigator: Medha N Munshi, MD         
Sponsors and Collaborators
Joslin Diabetes Center
Beth Israel Deaconess Medical Center
Boston Children’s Hospital
RTI International
Investigators
Layout table for investigator information
Principal Investigator: Medha N Munshi, MD Joslin Diabetes Center

Layout table for additonal information
Responsible Party: Joslin Diabetes Center
ClinicalTrials.gov Identifier: NCT03078491     History of Changes
Other Study ID Numbers: CHS #2016-29
First Posted: March 13, 2017    Key Record Dates
Last Update Posted: August 17, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Joslin Diabetes Center:
type 1 diabetes
geriatrics
older adults
technology
CGM
clinical decision support
hypoglycemia

Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Hypoglycemia
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Insulin
Hypoglycemic Agents
Physiological Effects of Drugs